EGFR非依赖的Elk1/CIP2A信号介导厄洛替尼衍生物TD52在三阴性乳腺癌细胞中的凋亡效应
研究探讨厄洛替尼衍生物TD52(对p-EGFR抑制微弱但显著下调CIP2A)在三阴性乳腺癌(TNBC)细胞中的疗效与机制。体外实验显示TD52经干扰Elk1与CIP2A启动子结合下调CIP2A、增加PP2A活性并诱导凋亡;裸鼠移植瘤中TD52具抗肿瘤活性并下调CIP2A与p-Akt。公共数据库分析显示CIP2A mRNA及Elk1 mRNA高表达与TNBC患者无复发生存更差相关。
要点
- TD52对p-EGFR抑制微弱但显著下调CIP2A,并诱导TNBC细胞凋亡。
- TD52经干扰Elk1与CIP2A启动子结合间接下调CIP2A转录。
- TD52在TNBC移植瘤小鼠中显示抗肿瘤活性并下调CIP2A与p-Akt。
核心结论
- 作者认为,EGFR非依赖的药理调节Elk1/CIP2A信号介导TD52在TNBC细胞中的凋亡效应,提示其潜在治疗策略。
研究设计与样本
- 体外研究使用三阴性乳腺癌(TNBC)细胞系,并通过裸鼠移植瘤体内实验检测TD52疗效。
- 细胞凋亡采用流式细胞术与Western blot检测,信号通路采用Western blot评估。
- 利用公开可及数据库分析CIP2A mRNA表达,并以Kaplan-Meier生存分析评估Elk1 mRNA表达与预后的关系。
主要发现
- 公开数据库分析显示,CIP2A mRNA水平较高与TNBC患者无复发生存更差相关。
- TD52诱导的凋亡伴随CIP2A下调,而CIP2A过表达可保护细胞免于TD52介导的凋亡。
- TD52处理细胞中蛋白磷酸酶2A(PP2A)活性升高,PP2A拮抗剂冈田酸减弱TD52诱导的凋亡与p-Akt下调。
- TD52通过干扰Elk1与CIP2A启动子的结合间接下调CIP2A转录。
- TD52在TNBC移植瘤小鼠中显示抗肿瘤活性,并下调移植瘤中的CIP2A与p-Akt;Kaplan-Meier分析显示Elk1 mRNA高表达亦与TNBC患者无复发生存更差相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Cancerous inhibitor of protein phosphatase 2A (CIP2A) has emerged as a therapeutic determinant mediating the anti-cancer effects of several new agents. We investigated the efficacy and mechanism of TD52, an erlotinib derivative with minimal p-EGFR inhibition but significant CIP2A downregulation, in triple-negative breast cancer (TNBC) cells. METHODS: TNBC lines were used for in vitro studies. Cell apoptosis was examined by flow cytometry and Western blot. Signal transduction pathways in cells were assessed by Western blot. In vivo efficacy of TD52 was tested in xenograft nude mice. RESULTS: We explored the CIP2A mRNA expression in a publically available database and found that higher levels of CIP2A mRNA is associated with worse recurrence-free survival in patients with TNBC. TD52-enhanced apoptosis accompanied with CIP2A downregulation and CIP2A overexpression protected cells from TD52-mediated apoptosis. The activity of protein phosphatase 2A (PP2A) was also increased in TD52-treated cells. TD52-induced apoptosis and p-Akt downregulation was attenuated by PP2A antagonist okadaic acid. Furthermore, TD52 indirectly downregulated CIP2A transcription via disturbing the binding of Elk1 to the CIP2A promoter. Importantly, TD52 showed anti-tumour activity in mice bearing TNBC xenograft tumours and downregulated CIP2A and p-Akt in these xenografted tumours. Interestingly, higher Elk1 mRNA expression was also associated with worse recurrence-free survival in TNBC patients by Kaplan-Meier survival analysis. CONCLUSION: Our findings indicated that EGFR-independent pharmacological modulation on Elk1/CIP2A signalling mediates the apoptotic effect of TD52 in TNBC cells, suggesting the potential therapeutic strategy.
引用
- Liu CY, Huang TT, Huang CT, et al. EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells. Eur J Cancer. 2016. PMID: 28027514. doi:10.1016/j.ejca.2016.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。